Radezolid

• CAT Number: I005232
• CAS Number: 869884-78-6
• Molecular Formula: C22H23FN6O3
• Molecular Weight: 438.45
• Purity: ≥95%
• Synonyms: N-[[(5S)-3-[3-fluoro-4-[4-[(2H-triazol-4-ylmethylamino)methyl]phenyl]phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide
• Target: Antibiotic
• Solubility: 10 mM in DMSO
• Storage: Store at -20°C
• InChI: InChI=1S/C22H23FN6O3/c1-14(30)25-12-19-13-29(22(31)32-19)18-6-7-20(21(23)8-18)16-4-2-15(3-5-16)9-24-10-17-11-26-28-27-17/h2-8,11,19,24H,9-10,12-13H2,1H3,(H,25,30)(H,26,27,28)/t19-/m0/s1
• InChIKey: BTTNOGHPGJANSW-IBGZPJMESA-N
• SMILES: CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)C3=CC=C(C=C3)CNCC4=NNN=C4)F

Radezolid（Cat No.:I005232）is an oxazolidinone antibiotic developed to target Gram-positive bacteria, including strains resistant to other antibiotics, such as MRSA and Streptococcus pneumoniae. It works by inhibiting bacterial protein synthesis through binding to the 50S ribosomal subunit, effectively stopping bacterial growth. Radezolid has shown promising activity in treating skin and soft tissue infections and is designed to improve on earlier oxazolidinones with enhanced potency and fewer side effects. Its strong tissue penetration and efficacy make it a valuable candidate for resistant infections, especially in research and clinical trials focused on multidrug-resistant bacteria.